Collegium Pharmaceutical

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell COLL and other ETFs, options, and stocks.

About COLL

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. 

CEO
Vikram Karnani
CEOVikram Karnani
Employees
357
Employees357
Headquarters
Stoughton, Massachusetts
HeadquartersStoughton, Massachusetts
Founded
2002
Founded2002
Employees
357
Employees357

COLL Key Statistics

Market cap
1.51B
Market cap1.51B
Price-Earnings ratio
29.82
Price-Earnings ratio29.82
Dividend yield
Dividend yield
Average volume
580.88K
Average volume580.88K
High today
$47.92
High today$47.92
Low today
$46.81
Low today$46.81
Open price
$47.59
Open price$47.59
Volume
267.59K
Volume267.59K
52 Week high
$48.37
52 Week high$48.37
52 Week low
$23.23
52 Week low$23.23

Stock Snapshot

Collegium Pharmaceutical(COLL) stock is priced at $47.91, giving the company a market capitalization of 1.51B. It carries a P/E multiple of 29.82.

During the trading session on 2025-12-07, Collegium Pharmaceutical(COLL) shares reached a daily high of $47.92 and a low of $46.81. At a current price of $47.91, the stock is +2.3% higher than the low and still -0.0% under the high.

Trading activity shows a volume of 267.59K, compared to an average daily volume of 580.88K.

Over the past 52 weeks, Collegium Pharmaceutical(COLL) stock has traded between a high of $48.37 and a low of $23.23.

Over the past 52 weeks, Collegium Pharmaceutical(COLL) stock has traded between a high of $48.37 and a low of $23.23.

COLL News

Simply Wall St 1d
Collegium Pharmaceutical: Assessing Valuation After Earnings Beats, Strong Zacks Rating and Value Investor Interest

Collegium Pharmaceutical (COLL) has jumped onto investors radars after a streak of earnings beats and a top research rating, with that momentum helping push the...

Collegium Pharmaceutical: Assessing Valuation After Earnings Beats, Strong Zacks Rating and Value Investor Interest

People also own

Based on the portfolios of people who own COLL. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.